Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Vasiliki K. Katsi, Christos A. Michalakeas, Charalambos E. Grassos, Georgia D. Vamvakou, John P. Lekakis, Dimitris Tousoulis, Christodoulos I. Stefanadis, Thomas K. Makris and Ioannis E. KallikazarosAffiliation:
Cardiology Department, Hippocratio Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.
AbstractCanagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.
Anti-diabetics, canagliflozin, hyperglycemia, invokana, sodium-glucose cotransporter-2 (SGLT2) inhibitors, type 2 diabetes mellitus.
Purchase Online Order Reprints Order Eprints Rights and Permissions